Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$2.02 -4.3%	$1.56	$1.09 ▼ $7.53	$149.83M	2.94	1.32 million shs	1.29 million shs
IOVA Iovance Biotherapeutics	$2.23 +14.9%	$1.91	$1.64 ▼ $12.51	$647.83M	0.85	9.32 million shs	24.60 million shs
TLRY Tilray Brands	$0.60 +1.6%	$0.46	$0.35 ▼ $2.15	$597.15M	1.82	31.10 million shs	23.24 million shs
URGN Urogen Pharma	$14.34 +2.1%	$10.18	$3.42 ▼ $17.27	$647.35M	1.02	1.09 million shs	775,779 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	-4.27%	0.00%	+23.93%	+61.60%	-72.63%
IOVA Iovance Biotherapeutics	+14.95%	+12.06%	+7.21%	-27.00%	-76.30%
TLRY Tilray Brands	+1.58%	-10.72%	+42.65%	+33.93%	-68.77%
URGN Urogen Pharma	+2.14%	+3.84%	0.00%	+48.29%	-16.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCCC C4 Therapeutics	3.0117 of 5 stars	3.3	4.0	0.0	3.3	1.7	0.6
IOVA Iovance Biotherapeutics	4.749 of 5 stars	4.2	1.0	4.2	2.9	4.2	1.3
TLRY Tilray Brands	1.8538 of 5 stars	3.1	1.0	0.0	3.2	0.0	1.3
URGN Urogen Pharma	4.3327 of 5 stars	4.5	2.0	4.5	1.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.50	Moderate Buy	$12.00	494.06% Upside
IOVA Iovance Biotherapeutics	2.33	Hold	$12.22	448.08% Upside
TLRY Tilray Brands	2.25	Hold	$1.92	218.01% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	129.13% Upside

Current Analyst Ratings Breakdown

Latest CCCC, IOVA, URGN, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$39.78M	3.61	N/A	N/A	$3.06 per share	0.66
IOVA Iovance Biotherapeutics	$164.07M	4.54	N/A	N/A	$2.33 per share	0.96
TLRY Tilray Brands	$788.94M	0.77	N/A	N/A	$4.14 per share	0.15
URGN Urogen Pharma	$90.40M	7.31	N/A	N/A	($0.21) per share	-68.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$105.32M	-$1.47	N/A	N/A	N/A	-259.60%	-45.86%	-28.96%	7/30/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
TLRY Tilray Brands	-$244.98M	-$1.05	N/A	N/A	N/A	-113.85%	-7.40%	-6.02%	8/4/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest CCCC, IOVA, URGN, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	URGN Urogen Pharma	-$0.85	N/A	N/A	N/A	$23.06 million	N/A
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.41	N/A	N/A	N/A	$5.24 million	N/A
8/4/2025	Q4 2025	TLRY Tilray Brands	-$0.03	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/7/2025	Q1 2025	CCCC C4 Therapeutics	-$0.48	-$0.37	+$0.11	-$0.37	$3.54 million	$7.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.70	5.70
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
TLRY Tilray Brands	0.12	2.62	1.61
URGN Urogen Pharma	N/A	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
IOVA Iovance Biotherapeutics	77.03%
TLRY Tilray Brands	9.35%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	8.73%
IOVA Iovance Biotherapeutics	10.30%
TLRY Tilray Brands	0.60%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	71.01 million	64.81 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
TLRY Tilray Brands	2,650	1.01 billion	1.00 billion	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

CCCC, IOVA, URGN, and TLRY Headlines

Recent News About These Companies

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit ...

July 16 at 4:21 AM | reflector.comR

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd.

July 15 at 8:32 PM | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

July 11, 2025 | globenewswire.com

UroGen Pharma Shows Market Leadership With Jump To 81 RS Rating

July 11, 2025 | msn.com

Urogen Pharma's (URGN) Buy Rating Reiterated at HC Wainwright

July 11, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC Wainwright

July 8, 2025 | marketbeat.com

UroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals

July 8, 2025 | tipranks.com

Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

July 8, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital

July 7, 2025 | marketbeat.com

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

July 7, 2025 | globenewswire.com

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer

July 6, 2025 | msn.com

Harel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)

July 4, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 1, 2025 | globenewswire.com

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

June 30, 2025 | globenewswire.com

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 30, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27, 2025 | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 23, 2025 | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (â€œUroGenâ€ or the â€œCompanyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Tilray Shares Blazing: What's Behind the 55% Rally This Month?
By Nathan Reiff | July 14, 2025
View Tilray Shares Blazing: What's Behind the 55% Rally This Month?
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

CCCC, IOVA, URGN, and TLRY Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$2.02 -0.09 (-4.27%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.03 +0.01 (+0.50%)

As of 06:21 AM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Iovance Biotherapeutics NASDAQ:IOVA

$2.23 +0.29 (+14.95%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.20 -0.02 (-1.12%)

As of 07:15 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Tilray Brands NASDAQ:TLRY

$0.60 +0.01 (+1.58%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.71%)

As of 07:15 AM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

Urogen Pharma NASDAQ:URGN

$14.34 +0.30 (+2.14%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$14.07 -0.27 (-1.88%)

As of 06:06 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time